Ed Miner, MD, FACC
Utah, Chapter President
ACC Governor, Utah

ACC Rockies Chapter Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.


For more information and to register, please visit: ACC Rockies Chapter Meeting 2026



ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • Fire-Sourced Air Pollution, Heat Waves Together Linked to Higher CV Mortality Risk
    Combined exposure to substantial fire-sourced air pollution (SFAP) and heat waves was associated with a higher excess risk of cardiovascular mortality than exposure to either hazard alone, according to a multicountry time-series study published July 29 in JACC.
  • ACC Survey Spotlights Burnout in CICU-Focused Clinicians
    Cardiac intensive care unit (CICU)-focused clinicians reported high job satisfaction, yet one in three also reported burnout, according to the first study to investigate burnout in this population, published March 25 in JACC: Advances.
  • Can Plasma Infrared Molecular Fingerprinting Stratify Residual Risk in Patients With CAD?
    Plasma infrared molecular fingerprinting (IMF) is able to stratify residual mortality risk in patients with coronary artery disease (CAD), outperforming guideline-recommended SMART2 scores and capturing clonal haematopoiesis of indeterminate potential (CHIP)-associated biology without the need for genomic sequencing...
  • ATTR-CM: Sex Differences, Delayed Diagnosis and Effect of Acoramidis
    Three recent studies, two published in JACC: Advances and a third published in JAMA Cardiology, investigate sex differences, delayed diagnosis and the effect of acoramidis on heart failure (HF)-related health status in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
  • ADVANCE OUTCOMES: Ralinepag Reduces Clinical Worsening For PAH
    Ralinepag, a selective prostacyclin IP receptor agonist, significantly reduced the risk of first clinical worsening compared with placebo in patients with pulmonary arterial hypertension (PAH) but was associated with more adverse-event-related treatment discontinuations, according to results of the ADVANCE OUTCOMES trial published July 28 in The Lancet.